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Abstract Genistein is an isoflavone that is known to be
contained in soybean. It was proved that genistein plays a
pivotal role in homeostasis in the human body. In the course of
screening for useful K-glucosidase inhibitors, we isolated and
identified genistein as a candidate for K-glucosidase inhibitor
from fermentation broths of a Streptomyces sp. Genistein was
shown to be a reversible, slow-binding, non-competitive inhibitor
of yeast K-glucosidase with a Ki value of 5.7U1038 M when the
enzyme mixture was pretreated with genistein. These results
show a possibility that genistein could be a useful tool for
metabolic disorders. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Glycosidases are not only essential to carbohydrate diges-
tion, but also vital for the processing of glycoproteins and
glycolipids. Glycosidases are also involved in a variety of
metabolic disorders and other diseases such as diabetes [1],
viral attachment [2] and cancer formation [3]. Because of their
importance, glycosidase inhibitors can be important tools for
studying their mechanisms of action and are also prospective
therapeutic agents for some degenerative diseases [4]. Gluco-
sidases are located in the brush-border surface membrane of
intestinal cells [5], and are the key enzymes of carbohydrate
digestion [6]. Some researchers have reported that oral admin-
istration of speci¢c K-glucosidase inhibitors could e¡ectively
improve hyperglycemia as well as diabetic complications [7,8].
Additionally, K-glucosidase inhibitors such as nojirimycin,
N-butyldeoxynojirimycin, and castanospermine are potent in-
hibitors of human immunode¢ciency virus (HIV) replication
and HIV-mediated syncytium formation in vitro [9^11]. Re-
cently, we found that genistein, isolated from Streptomyces
sp., slightly inhibited the action of DNA topoisomerase II
(data not shown). Interestingly, in the course of our search
for K-glucosidase inhibitors, genistein was isolated and iden-
ti¢ed as a potent K-glucosidase inhibitor (Fig. 1). In this
study, we describe the inhibitory mode of action of genistein
against K-glucosidase.
2. Materials and methods
2.1. Reagents
p-Nitrophenyl (PNP) glycosides used in this study were purchased
from Sigma (St. Louis, MO, USA). K-Glucosidase (from baker’s
yeast, Sigma), L-glucosidase (from almond, Sigma), K-mannosidase
(jack beans, Sigma), and L-mannosidase (from snail acetone powder,
Sigma) were commercially available. Genistein was isolated and puri-
¢ed from a Streptomyces sp. by various analytical procedures or was
commercially available (Sigma).
2.2. Enzyme assays
To evaluate whether genistein inhibits various commercially avail-
able glycosidases, the assay for glycosidases was done as described
previously [12,13]. In brief, K-glucosidase and the other glycosidases
were assayed using 50 mM phosphate bu¡er at pH 6.7, and the ap-
propriate PNP glycosides (at 1 mM) were used as substrates. The
concentration of the enzymes is speci¢ed in each experiment. Genis-
tein at the designated concentration was added to the enzyme solution
in the bu¡er and incubated at 30‡C for 1 h, and the substrate was
then added to initiate the enzyme reaction. When pretreatment is not
speci¢ed, mixtures of substrate and genistein at designated concentra-
tions were prepared beforehand and added to the enzyme solution.
The enzyme reaction was carried out at 30‡C for 30 min, and then
three volumes of 1 M Na2CO3 were added to terminate the reaction.
Enzymatic activity was quanti¢ed by measuring the absorbance at 405
nm. One unit of K-glucosidase and other glycosidases is de¢ned as the
amount of enzyme liberating 1.0 Wmol of PNP per minute under the
assay conditions speci¢ed.
2.3. Dialysis experiment
K-Glucosidase (0.5 ml, 100 U/ml) and genistein (10 WM) treated
for appropriate times at 30‡C were dialyzed against phosphate bu¡er
(5 mM, pH 6.7) at 4‡C for 24 h, changing the bu¡er every 12 h.
Another 0.5 ml aliquot was kept at 4‡C for 24 h without dialysis.
The contents in dialysis tubes were determined for residual enzyme
activity as described in Section 2.2.
2.4. Kinetics of enzyme inhibition
The enzyme reaction was performed according to the above reac-
tion conditions with inhibitors of various concentrations. Inhibition
types for the inhibitors were determined by Dixon plot and its replot
of slope versus the reciprocal of the substrate concentration [14].
3. Results
A potent K-glucosidase inhibitor was isolated and puri¢ed
from a Streptomyces sp. by various analytical procedures
(data not shown). We screened out one of 2160 fermentation
broths, and con¢rmed that the puri¢ed compound was genis-
tein (Fig. 1), which was identical to authentic genistein (Sig-
ma) (data not shown). Thereafter, we used genistein that is
commercially available (Sigma).
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As shown in Fig. 2, K-glucosidase was the most sensitive to
genistein, and the concentration required for 50% inhibition
(IC50) was 50 nM. At higher concentrations, genistein inhib-
ited the activities of K-mannosidase, L-mannosidase, and
L-glucosidase with sensitivities decreasing in that order. The
IC50 values were 840 nM, 4.5 WM and 18 WM, respectively.
This result shows that the activity of K-glucosidase is reduced
by genistein in a dose-responsive manner.
We ¢rst examined the e¡ects of genistein on inhibition of
K-glucosidase (Fig. 3). When we added 2 mM glucose to the
reaction mixture, the IC50 value was increased more than ¢ve-
fold. Therefore, we assumed that genistein at least partially
acts as an analog of glucose or binds to the glucose-binding
site of K-glucosidase. In Fig. 3A, we investigated whether the
IC50 value increased from 50 nM to 1.6 WM when the amount
of K-glucosidase in the reaction mixture was raised from 1.0
to 8.0 U/ml. The results partially suggest that the inhibitor
might bind to the glucose-binding site of K-glucosidase,
although the binding has not yet been investigated. The K-glu-
cosidase inhibitory activity by genistein was increased by pre-
incubation of the inhibitor with the enzyme (Fig. 3B). When
the substrate (1 mM) and genistein (10 WM) were added si-
multaneously, the IC50 was ca. 8.0 WM. This value was de-
creased 154-fold (ca. 50 nM) when K-glucosidase was treated
with genistein at 30‡C for 1 h before the initiation of enzyme
reaction.
To examine whether the inhibition of K-glucosidase by gen-
istein is reversible or not, the inhibitor (10 WM) was added
to K-glucosidase (100 U/ml) before dialysis. K-Glucosidase
(0.5 ml, 100 U/ml) and genistein (10 WM) treated for 2 h at
30‡C were dialyzed against phosphate bu¡er (5 mM, pH 6.7)
at 4‡C for 24 h, changing the bu¡er every 12 h. Another 0.5
ml aliquot was kept at 4‡C for 24 h without dialysis. The
contents in dialysis tubes were determined for residual enzyme
activity. When genistein alone was dialyzed with the bu¡er
completely, no inhibitory activity was detected even at
105-fold dilution (data not shown). The enzyme activity in
the dialysis membrane was similar with and without dialysis
(Fig. 4, compare E with a), while the activity of K-glucosidase
preincubated with genistein was not detected before dialysis
(Fig. 4, P), but the activity was recovered after dialysis
Fig. 1. The structure of genistein.
Fig. 2. Inhibition by genistein against various glucosidases. Enzyme
solutions were treated with designated concentrations of genistein.
The amount of enzymes were as follows: 1 U/ml K-glucosidase (a),
0.5 U/ml L-glucosidase (P), 0.5 U/ml K-mannosidase (E), 0.1 U/ml
L-mannosidase (R). The mixtures of enzyme and genistein were
kept at room temperature for 1 h.
Fig. 3. The IC50 value for the inhibition of K-glucosidase varies de-
pending on the amount of K-glucosidase (A) and on the time of
pretreatment with genistein (B). A: Di¡erent amounts (1, 2, 4, and
8 U/ml) of K-glucosidase were treated with genistein (10 WM) for
1 h. B: K-Glucosidase (1 U/ml) was pretreated with genistein
(10 WM) for 0^120 min in phosphate bu¡er (50 mM, pH 6.7) at
30‡C. After pretreatment of K-glucosidase with genistein, PNP-K-
glucopyranoside was added to the mixture to initiate the reaction.
The IC50 values were determined by quantifying the PNP liberated.
Fig. 4. The recovery of inhibitory action of genistein against K-glu-
cosidase after dialysis. The inhibitor (10 WM) was added to K-gluco-
sidase (100 U/ml) before dialysis. K-Glucosidase (0.5 ml, 100 U/ml)
and genistein (10 WM) treated for 2 h at 30‡C were dialyzed against
phosphate bu¡er (5 mM, pH 6.7) at 4‡C for 24 h, changing the
bu¡er every 12 h. Another 0.5 ml aliquot was kept at 4‡C for 24 h
without dialysis. K-Glucosidase alone (E,a) and K-glucosidase/genis-
tein (P,R) were dialyzed against 5 mM phosphate bu¡er (pH 7.0)
at 4‡C (a,R) or were kept at 4‡C (E,P) for 24 h.
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(Fig. 4, R). These results show that inhibition mode of
genistein against K-glucosidase is reversible.
Double-reciprocal plots of K-glucosidase kinetics with gen-
istein are shown in Fig. 5. Non-competitive inhibition was
partially observed when genistein and substrate were added
simultaneously, showing a Ki value of 500 nM (data not
shown). The enzyme activity was also inhibited non-compet-
itively when the enzyme was pretreated with genistein (10 WM)
for 1 h. At this point, the Ki value was 57 WM (Fig. 5). This Ki
value was calculated using the values of Vmax obtained at
0 and 0.8 WM of genistein.
4. Discussion
There is much evidence suggesting that compounds present
in soybeans can prevent cancer in many di¡erent organ sys-
tems [15], although the evidence for speci¢c soybean-derived
compounds having a suppressive e¡ect on carcinogenesis in
animal model systems is limited [16]. It is well known that soy
iso£avone genistein attenuates growth factor- and cytokine-
stimulated proliferation in cancer cells [17]. Genistein is also a
potent and speci¢c inhibitor of tyrosine autophosphorylation
of the epidermal growth factor receptor. Additionally, its
mode of action includes inhibition of DNA topoisomerase
II activity, regulation of cell cycle checkpoints, and antiangio-
genic and antioxidant activities [15,16]. In the course of devel-
opment of K-glucosidase inhibitors from microbial sources, we
found genistein, a soy iso£avone, as a candidate for K-gluco-
sidase inhibitors (Fig. 1). We show in this study that genistein
is a potent K-glucosidase inhibitor suggesting that genistein
could be a useful tool for metabolic disorders.
We ¢rst examined whether genistein speci¢cally inhibits
K-glucosidase. The activity of K-glucosidase is reduced by
genistein in a dose-responsive manner (Fig. 2). We concluded
that genistein may bind to K-glucosidase, and K-glucosidase
inhibitory activity by genistein was increased by preincubation
of the inhibitor with the enzyme (Fig. 3). Because the time
required to reach the binding equilibrium varies with the en-
zyme concentration (Figs. 2 and 3), the inhibition mode seems
to be a slow-binding capability. A comparison of the plots
indicates that the enzyme treated with the inhibitor followed
by dialysis (Fig. 4, R) required a concentration about 20-fold
higher than the control (dialyzed enzyme without inhibitor,
Fig. 4, a) to attain the same enzyme activity. At least, the
dialysis experiment showed that the inhibition of K-glucosi-
dase by genistein might be reversible. Double-reciprocal plots
of K-glucosidase with genistein revealed that the mode of en-
zyme inhibition was non-competitive when the enzyme was
pretreated with genistein for 1 h. In present study, the data
partially suggest that genistein o¡ers a possibility of being
developed as successful K-glucosidase inhibitor.
In conclusion, the results suggest that genistein could be
used for mechanism studies on the glycosylation of some met-
abolic diseases. The inhibition studies provide useful informa-
tion for the design of new potent inhibitors for glycosidases.
To date, the yeast K-glucosidase is known to be very di¡erent
from mammalian digestive enzymes, suggesting that ongoing
experiments should be focused on the inhibitory activity of
genistein against mammalian intestinal K-glucosidases. Fur-
ther studies on the elucidation of molecular mechanisms of
trimming and the inhibition mode of action of more potent
genistein derivatives against K-glucosidase could also be re-
warding.
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Fig. 5. Double-reciprocal plots of the inhibition kinetics of yeast
K-glucosidase by genistein. K-Glucosidase (50 Wl, 10 U/ml) that was
treated ¢rst with genistein for 1 h at 30‡C was treated with a mix-
ture of 50 Wl of each designed concentration of PNP-K-glucopyrano-
side to initiate the enzyme reaction.
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